205 related articles for article (PubMed ID: 32160755)
1. Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.
Dubé K; Hosey L; Starr K; Barr L; Evans D; Hoffman E; Campbell DM; Simoni J; Sugarman J; Sauceda J; Brown B; Diepstra KL; Godfrey C; Kuritzkes DR; Wohl DA; Gandhi R; Scully E
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):268-282. PubMed ID: 32160755
[TBL] [Abstract][Full Text] [Related]
2. Perceptions of HIV Virologic Control Strategies Among Younger and Older Age Groups of People Living with HIV in the United States: A Cross-Sectional Survey.
Saberi P; Eskaf S; Sauceda J; Evans D; Dubé K
AIDS Res Hum Retroviruses; 2020 Jul; 36(7):606-615. PubMed ID: 32368934
[TBL] [Abstract][Full Text] [Related]
3. Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.
Diepstra KL; Barr L; Palm D; Hogg E; Mollan KR; Henley L; Stover AM; Simoni JM; Sugarman J; Brown B; Sauceda JA; Deeks S; Fox L; Gandhi RT; Smith D; Li JZ; Dubé K
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):489-501. PubMed ID: 33472545
[TBL] [Abstract][Full Text] [Related]
4. "I would really want to know that they had my back": Transgender women's perceptions of HIV cure-related research in the United States.
Poteat T; Aqil A; Corbett D; Evans D; Dubé K
PLoS One; 2020; 15(12):e0244490. PubMed ID: 33382760
[TBL] [Abstract][Full Text] [Related]
5. Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners.
Henderson GE; Waltz M; Meagher K; Cadigan RJ; Jupimai T; Isaacson S; Ormsby NQ; Colby DJ; Kroon E; Phanuphak N; Ananworanich J; Peay HL
J Int AIDS Soc; 2019 Mar; 22(3):e25260. PubMed ID: 30869203
[TBL] [Abstract][Full Text] [Related]
6. The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.
Dubé K; Eskaf S; Evans D; Sauceda J; Saberi P; Brown B; Averitt D; Martel K; Meija M; Campbell D; Barr L; Kanazawa J; Perry K; Patel H; Luter S; Poteat T; Auerbach JD; Wohl DA
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):324-348. PubMed ID: 31608651
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.
Valente PK; Wu Y; Cohen YZ; Caskey M; Meyers K
Clin Trials; 2021 Feb; 18(1):17-27. PubMed ID: 32838558
[TBL] [Abstract][Full Text] [Related]
8. Impact of dedicated women's outreach workers (WOWs) on recruitment of women in ACTG clinical studies.
Barr E; Dubé K; Swaminathan S; Del Rio C; Campbell DM; Paez-Quinde M; Cohn SE
HIV Res Clin Pract; 2021 Apr; 22(2):37-45. PubMed ID: 34143949
[TBL] [Abstract][Full Text] [Related]
9. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Scully EP; Aga E; Tsibris A; Archin N; Starr K; Ma Q; Morse GD; Squires KE; Howell BJ; Wu G; Hosey L; Sieg SF; Ehui L; Giguel F; Coxen K; Dobrowolski C; Gandhi M; Deeks S; Chomont N; Connick E; Godfrey C; Karn J; Kuritzkes DR; Bosch RJ; Gandhi RT
Clin Infect Dis; 2022 Oct; 75(8):1389-1396. PubMed ID: 35176755
[TBL] [Abstract][Full Text] [Related]
10. 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States.
Dubé K; Taylor J; Sylla L; Evans D; Dee L; Burton A; Willenberg L; Rennie S; Skinner A; Tucker JD; Weiner BJ; Greene SB
PLoS One; 2017; 12(1):e0170112. PubMed ID: 28122027
[TBL] [Abstract][Full Text] [Related]
11. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.
Voytek CD; Jones KT; Metzger DS
Vaccine; 2011 Aug; 29(36):6130-5. PubMed ID: 21704110
[TBL] [Abstract][Full Text] [Related]
12. Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings.
Saberi P; Campbell CK; Sauceda JA; Ndukwe S; Dubé K
AIDS Res Hum Retroviruses; 2022 Aug; 38(8):649-659. PubMed ID: 35579937
[TBL] [Abstract][Full Text] [Related]
13. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
[TBL] [Abstract][Full Text] [Related]
14. Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States.
Dubé K; Barr E; Philbin M; Perez-Brumer A; Minalga B; Peterson B; Averitt D; Picou B; Martel K; Chung C; Mejía M; Cameron M; Graham G; Dee L; Dixon Diallo D; Gordon E; Korolkova A; Dyer T; Auerbach JD; Scully E; Dong KL; Gianella S
HIV Res Clin Pract; 2023 Aug; 24(1):2246717. PubMed ID: 37608645
[TBL] [Abstract][Full Text] [Related]
15. The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices.
Peterson IS; Mazzella AJ; Belter LT; Curry MA; Cruz RE; Jarecki J
Neurol Ther; 2022 Sep; 11(3):1167-1181. PubMed ID: 35635603
[TBL] [Abstract][Full Text] [Related]
16. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
[TBL] [Abstract][Full Text] [Related]
17. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.
Henderson GE; Peay HL; Kroon E; Cadigan RJ; Meagher K; Jupimai T; Gilbertson A; Fisher J; Ormsby NQ; Chomchey N; Phanuphak N; Ananworanich J; Rennie S
J Med Ethics; 2018 Apr; 44(4):270-276. PubMed ID: 29127137
[TBL] [Abstract][Full Text] [Related]
18. Perceptions of barriers and facilitators to participation in clinical trials in HIV-positive Latinas: a pilot study.
Zúñiga ML; Blanco E; Martínez P; Strathdee SA; Gifford AL
J Womens Health (Larchmt); 2007 Nov; 16(9):1322-30. PubMed ID: 18001189
[TBL] [Abstract][Full Text] [Related]
19. A global survey of HIV-positive people's attitudes towards cure research.
Simmons R; Kall M; Collins S; Cairns G; Taylor S; Nelson M; Fidler S; Porter K; Fox J;
HIV Med; 2017 Feb; 18(2):73-79. PubMed ID: 27167600
[TBL] [Abstract][Full Text] [Related]
20. Using perceptual mapping methods to understand gender differences in perceived barriers and benefits of clinical research participation in urban minority HIV+ patients.
Bass SB; Wolak C; Greener J; Tedaldi E; Nanavati A; Ruppert K; Gordon TF
AIDS Care; 2016; 28(4):528-36. PubMed ID: 26572215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
